BACKGROUND: Guidelines advocate >7d of broad-spectrum antibiotics for unexplained fever (UF) during neutropaenia. However, effective antimicrobial prophylaxis reduces the incidence of gram-negative infections, which may allow shorter treatment. This study evaluates the safety of discontinuing empirical broad-spectrum antibiotics if no microbial source is documented after an initial work-up of 72 h. METHODS: Prospective observational study at a tertiary-care haematology-unit in patients suffering from haematologic malignancies and treatment-induced prolonged neutropaenia of 10d. Oral fluoroquinolone and fluconazole prophylaxis was given from day 1. Fever was empirically treated with imipenem which was discontinued after 72 h if, following a standardised protocol, no infectious aetiology was documented. Duration of fever, antimicrobial therapy and overall mortality were registered. RESULTS: One hundred and sixty six patients were evaluated during 276 neutropaenic episodes. One hundred and thirty six patients (82.5%) experienced 1 febrile episode. A total of 317 febrile episodes were observed, of which 177 (56%) were diagnosed as UF. In 135 febrile episodes (43%), a probable/definite infectious origin was documented. Mean duration of fever in neutropaenic periods with 1 febrile episode was 5d, and mean time of treatment with imipenem was 4.7d. In patients without documented infection, mean time of imipenem treatment was only 3.7d. Overall mortality 30 d after neutrophil recovery was 3.6% (6/166); no patient died from untreated bacterial infection. CONCLUSION: Discontinuation of broad-spectrum antibiotics during neutropaenia in haematology patients on fluoroquinolone and fluconazole prophylaxis is safe, provided that no infectious aetiology is established after 72 h.
BACKGROUND: Guidelines advocate >7d of broad-spectrum antibiotics for unexplained fever (UF) during neutropaenia. However, effective antimicrobial prophylaxis reduces the incidence of gram-negative infections, which may allow shorter treatment. This study evaluates the safety of discontinuing empirical broad-spectrum antibiotics if no microbial source is documented after an initial work-up of 72 h. METHODS: Prospective observational study at a tertiary-care haematology-unit in patients suffering from haematologic malignancies and treatment-induced prolonged neutropaenia of 10d. Oral fluoroquinolone and fluconazole prophylaxis was given from day 1. Fever was empirically treated with imipenem which was discontinued after 72 h if, following a standardised protocol, no infectious aetiology was documented. Duration of fever, antimicrobial therapy and overall mortality were registered. RESULTS: One hundred and sixty six patients were evaluated during 276 neutropaenic episodes. One hundred and thirty six patients (82.5%) experienced 1 febrile episode. A total of 317 febrile episodes were observed, of which 177 (56%) were diagnosed as UF. In 135 febrile episodes (43%), a probable/definite infectious origin was documented. Mean duration of fever in neutropaenic periods with 1 febrile episode was 5d, and mean time of treatment with imipenem was 4.7d. In patients without documented infection, mean time of imipenem treatment was only 3.7d. Overall mortality 30 d after neutrophil recovery was 3.6% (6/166); no patient died from untreated bacterial infection. CONCLUSION: Discontinuation of broad-spectrum antibiotics during neutropaenia in haematology patients on fluoroquinolone and fluconazole prophylaxis is safe, provided that no infectious aetiology is established after 72 h.
Authors: Jessica M van der Bol; Floris A de Jong; Ron H van Schaik; Alex Sparreboom; Marianne A van Fessem; Fleur E van de Geijn; Paul L van Daele; Jaap Verweij; Stefan Sleijfer; Ron H Mathijssen Journal: Oncologist Date: 2010-10-07
Authors: J R de la Court; A H W Bruns; A H E Roukens; I O Baas; K van Steeg; M L Toren-Wielema; M Tersmette; N M A Blijlevens; R A G Huis In 't Veld; T F W Wolfs; W J E Tissing; Y Kyuchukova; J Heijmans Journal: Infect Dis Ther Date: 2022-10-14
Authors: Diana Averbuch; Christina Orasch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova Journal: Haematologica Date: 2013-12 Impact factor: 9.941
Authors: Risa Fuller; Erin Moshier; Samantha E Jacobs; Douglas Tremblay; Guido Lancman; Alexander Coltoff; Jessica Caro; John Mascarenhas; Meenakshi Rana Journal: Open Forum Infect Dis Date: 2020-04-21 Impact factor: 3.835
Authors: A Schauwvlieghe; A Dunbar; E Storme; A Vlak; R Aerts; J Maertens; B Sciot; T Van Der Wel; G Papageorgiou; I Moors; J J Cornelissen; B J A Rijnders; T Mercier Journal: EClinicalMedicine Date: 2021-04-25
Authors: W J Heinz; D Buchheidt; M Christopeit; M von Lilienfeld-Toal; O A Cornely; H Einsele; M Karthaus; H Link; R Mahlberg; S Neumann; H Ostermann; O Penack; M Ruhnke; M Sandherr; X Schiel; J J Vehreschild; F Weissinger; G Maschmeyer Journal: Ann Hematol Date: 2017-08-30 Impact factor: 3.673
Authors: F A Niessen; M S M van Mourik; A H W Bruns; R A P Raijmakers; M C H de Groot; T van der Bruggen Journal: Antimicrob Resist Infect Control Date: 2020-05-27 Impact factor: 4.887